Hims & Hers recently announced its $1.15B acquisition of Eucalyptus, an Australian digital health company.

In an interview with MedCity News, Managing Partner Michael Abrams shared his thoughts on the deal, noting that it’s a smart move, both financially and strategically.

By bringing Eucalyptus into the fold, Hims & Hers is making a deliberate pivot from a largely U.S.-centric telehealth and DTC model to a global consumer health platform.

Strategically, the Eucalyptus acquisition gives Hims & Hers geographic diversification away from its core U.S. markets — a move likely designed in part to de-risk revenue concentration and broaden patient bases.

The deal is particularly significant as U.S. regulatory scrutiny around compounded GLP-1s has highlighted the risks of concentration in any single market or product category. International expansion helps de-risk that exposure while opening new pathways for growth in high-demand verticals like weight management, dermatology, and reproductive health.

Read the full story at medcitynews.com.